Cloetta AB ser. B (0N7X)
London Exchange · UK · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 55.88 |
|---|---|
| 52-week range | 32.39 – 58.40 |
| Return, 1 month / 3 months | +5.5% / −0.4% |
| Return, 1 year / 3 years | +58.1% / +268.6% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 30.4% |
| Worst drawdown (1 year) | -14.9% |
| Average daily value traded | 1.50M SEK |
| Dividend yield | 2.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cloetta AB is a Swedish confectionery company that makes and markets chocolate, pastilles, chewing gum, sweets and other sugar confectionery. Its brands include Läkerol, Kexchoklad, Ahlgrens bilar and Malaco, sold through grocery retailers, convenience stores and other outlets in Sweden and across northern Europe. The company is based in Sweden and serves consumers who buy everyday treats and pick-and-mix sweets.
The shares are listed on the London Exchange in UK under the code 0N7X, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cloetta AB ser. B (0N7X) trades on the London Exchange in UK. It last closed at SEK 55.88 on 19 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 584 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 58.1% and over the last three months it fell 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 77 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.5% | ||
| From 52-week high | -3.2% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -0.4% | ||
| 6-month return | 14.7% | ||
| 12-month return, skipping the last month | 49.8% | ||
| Stability (higher is calmer) | 74 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 30.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -14.9% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.50M SEK | ||
| Zero-volume days | 3.3% | ||
| Income | 53 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.5% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +7.3% |
|---|---|
| 1 month | +5.5% |
| 3 months | −0.4% |
| 6 months | +14.7% |
| 1 year | +58.1% |
| 3 years | +268.6% |
| 5 years | +152.4% |
Signals
| 50-day / 200-day average | 53.79 / 50.56 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.72 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Apr 2026 | SEK 1.4000 |
| 11 Apr 2025 | SEK 1.1000 |
| 10 Apr 2024 | SEK 1.0000 |
| 5 Apr 2023 | SEK 1.0000 |
| 7 Apr 2022 | SEK 1.0000 |
| 7 Apr 2021 | SEK 0.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.